Finns consider extending breast screening age:
This article was originally published in Clinica
Executive Summary
A number of Finnish municipalities will need "notable extra resources" to extend the upper age limit of its breast cancer screening programme from 59 to 69 years, as recently recommended by the health technology assessment agency, FinOHTA. Nationally, there are sufficient screening devices and experienced professionals, but their geographical distribution is uneven, says FinOHTA. "It is likely that the ministry will give guidance on extending screening to older age groups, but has not made a firm decision yet," Marjukka Makela, research professor at FinOHTA, told Clinica. FinOHTA estimated the cost per life-year saved by mammography screening to be FMk36,600 ($5,500). When all factors were varied within reasonable limits, the estimate ranged from FMk11,600 to FMk223,000.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.